Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-06-15 Regulatory Filings
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA Announces First Patient Dosed in the Phase II INITIUM Trial in Metastatic Malignant Melanoma
Regulatory Filings Classification · 99% confidence The document is an announcement from Ultimovacs ASA detailing a clinical trial milestone: dosing the first patient in the Phase II INITIUM trial for metastatic malignant melanoma. It includes quotes from the CEO and CMO, details about the trial design (UV1 combination therapy), expected results timeline (H2 2022), and mentions other ongoing trials (NIPU). This content is characteristic of a press release providing operational and clinical updates to investors, rather than a formal regulatory filing like a 10-K, a formal earnings release (ER), or a specific legal/governance document. Since it is a general announcement about company progress and clinical development, it fits best under the general 'Regulatory Filings' (RNS) category as a significant operational update, although it is not a standard SEC form. Given the options, RNS serves as the best fit for a general corporate press release announcing a clinical milestone.
2020-06-15 English
Ultimovacs ASA Announces First Patient Enrolled in the NIPU Phase II Clinical Trial Testing UV1 Against Mesothelioma
Regulatory Filings Classification · 95% confidence The document is an announcement from Ultimovacs ASA regarding the enrollment of the first patient in a Phase II clinical trial (NIPU trial) for their product UV1 against mesothelioma. It details the trial design, collaborators (Bristol-Myers Squibb, Oslo University Hospital), endpoints, and expected readout dates. This type of announcement, focusing on clinical trial progress and updates, is best classified as a general corporate or regulatory update, as it does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Since it is a specific operational update that doesn't fit the other specialized categories, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for significant, non-financial, non-management corporate news.
2020-06-15 English
Ultimovacs ASA – New share capital registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that a 'New share capital registered' following a previously announced private placement. It details the resulting share capital amount and the total number of shares. This directly relates to a change in the company's capital structure, specifically the issuance of new shares resulting from a financing activity. This aligns best with the 'Share Issue/Capital Change' definition (SHA). It is not a general financing update (CAP) but a confirmation of the capital structure change post-financing.
2020-06-05 English
Ultimovacs ASA - Private placement of new shares successfully placed
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the successful completion of a 'Private placement of new shares' by Ultimovacs ASA, detailing the number of shares allocated, the subscription price, and the gross proceeds raised (NOK 160 million). It also details the resulting change in share capital and insider allocations. This activity directly relates to the company raising capital and changing its capital structure through the issuance of new shares. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). While it involves shares, it is a specific financing event rather than a general share repurchase (POS) or a general share issue announcement (SHA), making CAP the most precise fit.
2020-05-27 English
Ultimovacs ASA - Contemplated private placement
Capital/Financing Update Classification · 99% confidence The document is titled "Ultimovacs ASA - Contemplated private placement" and discusses the intent to issue new shares via a private placement to raise NOK 160 million. It details the bookbuilding process, pre-commitments from underwriters, and restrictions on distribution (e.g., not for release in the US, Australia, etc.). This content directly relates to fundraising, financing activities, and changes to the capital structure (issuing new shares). This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA).
2020-05-27 English
Ultimovacs ASA Announces Collaboration with Big Pharma Company and Leading European Oncology Clinical Trial Group to Evaluate UV1 in a Third Phase II Clinical Trial
Capital/Financing Update Classification · 95% confidence The document is a press release from Ultimovacs ASA announcing a new collaboration for a Phase II clinical trial involving their drug UV1. It details the expansion of their clinical program, mentions expected enrollment timelines, and discusses financing via a private placement. This type of announcement, focusing on business development, clinical progress, and financing updates, is characteristic of a general corporate announcement or a capital/financing update. Since it explicitly mentions a 'private placement' to finance the development program, the 'Capital/Financing Update' (CAP) category is highly relevant. It is not a formal regulatory report (like 10-K or IR), nor is it a transcript or a formal presentation. Given the strong emphasis on financing the trial expansion, CAP is the most precise fit over a general Regulatory Filing (RNS).
2020-05-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.